Immunotherapy has emerged as a promising treatment paradigm for many malignancies
and is transforming the drug development landscape. Although immunotherapeutic agents …

Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing
technology represents a significant breakthrough in personalized immunotherapy for human …

CAR T cell-based therapies have revolutionized the treatment of hematological
malignancies such as leukemia and lymphoma within the last years. In contrast to the …

Metastatic uveal melanoma is less well understood than its primary counterpart, has a
distinct biology compared to skin melanoma, and lacks effective treatments. Here we …

Due to the overexpression or amplification of human epidermal growth factor receptor 2
(HER2) with poor prognosis in a myriad of human tumors, recent studies have focused on …

Metastatic disease from uveal melanoma occurs in almost 50% of patients suffering from this
ocular tumour, with median survival from development of symptoms being around 1 year. In …

Simple Summary Uveal melanoma is the most common primary intraocular malignancy in
adults. Although it can be controlled locally, half of the patients still develop metastases. To …

Clustered regularly interspaced short palindromic repeats‐associated protein
(CRISPR/Cas9), an adaptive microbial immune system, has been exploited as a robust …

GBM is the most common primary brain tumor in adults, and the aggressive nature of this
tumor contributes to its extremely poor prognosis. Over the years, the heterogeneous and …

Triple‐negative breast cancer (TNBC) is a very aggressive malignant type of tumor that
currently lacks effective targeted therapies. In hematological malignancies, chimeric antigen …